Surge in Public Offerings Led by Madison Air and Healthcare Sector

Key Facts

1Madison Air announced the pricing of its $2.23 billion IPO at $27.00 per share.

2Spyre Therapeutics priced an upsized $403 million public offering at $62.00 per share.

3Allogene Therapeutics announced a $175 million public offering priced at $2.00 per share.

4HeartBeam announced the pricing of a $10 million public offering.

Financial markets are maintaining strong momentum in capital-raising activities, highlighted by Trevi Therapeutics pricing its public offering of 11,600,000 shares at $13.00 per share. The company granted underwriters a 30-day option for an additional 1,740,000 shares, with the offering expected to close on April 20, 2026, to fund its Haduvio™ chronic cough therapy. This follows Kailera Therapeutics' recent Nasdaq listing at $16.00 per share, aimed at advancing obesity treatments. The broader healthcare surge includes Spyre Therapeutics' $463.5 million raise and Madison Air’s dominant $2.23 billion offering. Additionally, firms like Allogene Therapeutics and HeartBeam continue to tap into market liquidity, signaling robust investor appetite for clinical-stage biotech developments.

5 months ago

Version History

Version 45 months ago

What changed: Updated with specific pricing details for Trevi Therapeutics ($13.00/share), share volume, the underwriter over-allotment option, and the expected closing date.

Version 35 months ago

What changed: The story was updated to include the IPO pricing and Nasdaq listing details for Kailera Therapeutics.

Version 25 months ago

What changed: The story was updated to include Trevi Therapeutics' announcement of a new $150 million public offering.

Version 15 months ago

What changed: Updated the story to reflect the successful closing of Spyre Therapeutics' offering with increased total proceeds of $463.5 million following the full exercise of the over-allotment option.